After two years of successful valproic acid treatment, only patients that had developed obesity had significantly lower plasma ghrelin levels compared to controls, while this was not the case in patients that had not developed obesity [83]. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.